Abstract
Axitinib (Pfizer Inc., UK) is an oral small-molecule receptor tyrosine kinase inhibitor that targets angiogenesis. Axitinib has greater affinity and is a more selective inhibitor of VEGF receptor 1, -2 and -3, PDGFR and c-KIT than both sunitinib and sorafenib. It has encouraging efficacy and safety data in Phase II trials for metastatic renal cell carcinoma and advanced thyroid cancer patients. It is now being investigated in two Phase III trials in metastatic renal cell carcinoma and in Phase II trials in a range of tumor types. These trials will determine whether axitinib is an effective and safe antiangiogenic therapy.
MeSH terms
-
Angiogenesis Inhibitors / chemistry
-
Angiogenesis Inhibitors / pharmacokinetics*
-
Angiogenesis Inhibitors / therapeutic use*
-
Antineoplastic Combined Chemotherapy Protocols
-
Axitinib
-
Carcinoma, Renal Cell / drug therapy*
-
Carcinoma, Renal Cell / secondary*
-
Clinical Trials as Topic
-
Humans
-
Imidazoles / chemistry
-
Imidazoles / pharmacokinetics*
-
Imidazoles / pharmacology
-
Imidazoles / therapeutic use*
-
Indazoles / chemistry
-
Indazoles / pharmacokinetics*
-
Indazoles / pharmacology
-
Indazoles / therapeutic use*
-
Kidney Neoplasms / drug therapy
-
Neoplasms / drug therapy
-
Protein Kinase Inhibitors / chemistry
-
Protein Kinase Inhibitors / pharmacokinetics*
-
Protein Kinase Inhibitors / therapeutic use
Substances
-
Angiogenesis Inhibitors
-
Imidazoles
-
Indazoles
-
Protein Kinase Inhibitors
-
Axitinib